Intelligence Β· Clinical Pipeline
Rani Therapeutics Holdings Pipeline
All ClinicalTrials.gov programs at Rani Therapeutics Holdings β phase, modality, and trial IDs.
- Programs
- 7
Quick answer
Rani Therapeutics Holdings has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Berubicin hydrochloride
Rani Therapeutics Holdings
central nervous system (CNS) lymphomas
1 trial -
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
RT-102 (80 ΞΌg)
Rani Therapeutics Holdings
Healthy Volunteers
1 trial -
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity
Rani Therapeutics Holdings
Obesity
1 trial -
RaniPill capsule containing octreotide
Rani Therapeutics Holdings
Healthy Volunteers
1 trial -
Stelara
Rani Therapeutics Holdings
Healthy Volunteers
1 trial
Frequently asked questions
How many pipeline programs does Rani Therapeutics Holdings have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources Β· All pipeline programs